My Photo
Name:
Location: BACLIFF, Texas, United States

My mother was murdered by what I call corporate and political homicide i.e. FOR PROFIT! she died from a rare phenotype of CJD i.e. the Heidenhain Variant of Creutzfeldt Jakob Disease i.e. sporadic, simply meaning from unknown route and source. I have simply been trying to validate her death DOD 12/14/97 with the truth. There is a route, and there is a source. There are many here in the USA. WE must make CJD and all human TSE, of all age groups 'reportable' Nationally and Internationally, with a written CJD questionnaire asking real questions pertaining to route and source of this agent. Friendly fire has the potential to play a huge role in the continued transmission of this agent via the medical, dental, and surgical arena. We must not flounder any longer. ...TSS

Saturday, July 07, 2012

Class II, Blood products, collected from a donor who was at risk for variant Creutzfeldt-Jakob disease ( vCJD) USA

Enforcement Report


FDA Home3


Enforcement Reports4


Back to Event List


Event Detail


Event ID 61992


Product Type Biologics


Status Terminated


Recalling Firm Blood Assurance Inc


City Chattanooga


State TN


Country US


Voluntary/Mandated Voluntary: Firm Initiated


Recall Initiation Date 2012-05-01


Initial Firm Notification of


Consignee or Public FAX


Distribution Pattern TN, GA, NY


Product Detail


Product Description Code Info Classification Reason for Recall Product Quantity Recall Number


Plasma Cryoprecipitated Reduced W043210088572 Class II Blood products, collected from a donor who was at risk for variant Creutzfeldt-Jakob disease (vCJD), were distributed. 1 unit B-2009-12





Red Blood Cells (Apheresis) Leukocytes Reduced W043211094961-A; W043211094961-B; W043211044082-A; W043211025338-A; W043211044082-B; W043211025338-B Class II Blood products, collected from a donor who was at risk for variant Creutzfeldt-Jakob disease (vCJD), were distributed. 6 units B-2010-12





Cryoprecipitated AHF, Pooled W043210088572 Class II Blood products, collected from a donor who was at risk for variant Creutzfeldt-Jakob disease (vCJD), were distributed. 1 unit B-2011-12





Red Blood Cells Leukocytes Reduced V89413; V26698; W043210088572; W043210075817 Class II Blood products, collected from a donor who was at risk for variant Creutzfeldt-Jakob disease (vCJD), were distributed. 4 units B-2012-12





Plasma Frozen within 24 hours (FP24) W043210075817 Class II Blood products, collected from a donor who was at risk for variant Creutzfeldt-Jakob disease (vCJD), were distributed. 1 unit B-2013-12





Blood and Blood Products for Reprocessing V89413 Class II Blood products, collected from a donor who was at risk for variant Creutzfeldt-Jakob disease (vCJD), were distributed. 1 unit B-2014-12





Fresh Frozen Plasma V26698 Class II Blood products, collected from a donor who was at risk for variant Creutzfeldt-Jakob disease (vCJD), were distributed. 1 unit B-2015-12





Monday, June 11, 2012


Guidance for Industry Draft Guidance for Industry: Amendment to “Guidance for Industry: Revised Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products”


IN SHORT ;


“However, based on animal studies, as well as on FDA risk assessments, the possibility of vCJD transmission by a U.S.-licensed plasma derivative, while extremely small, cannot be absolutely ruled out. For these reasons, the recommendations for labeling for plasma derivatives will include mention of vCJD for the first time, and the potential risk for its transmission. The recommended elements of the warning label for CJD are unchanged and continue to describe its transmission as a theoretical risk, given that there is no confirmed evidence that CJD is transmitted by blood (Refs. 4-7).“




IN FULL, as follows ;


Monday, June 11, 2012


Guidance for Industry Draft Guidance for Industry: Amendment to “Guidance for Industry: Revised Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products”





Friday, June 29, 2012


Highly Efficient Prion Transmission by Blood Transfusion





Sunday, June 3, 2012


A new neurological disease in primates inoculated with prion-infected blood or blood components





Wednesday, June 27, 2012


First US BSE Case Since 2006 Underscores Need for Vigilance


Neurology Today 21 June 2012





Tuesday, June 26, 2012


Creutzfeldt Jakob Disease Human TSE report update North America, Canada, Mexico, and USDA PRION UNIT as of May 18, 2012


type determination pending Creutzfeldt Jakob Disease (tdpCJD), is on the rise in Canada and the USA





Wednesday, April 25, 2012


USA MAD COW DISEASE AND CJD THERE FROM SINGELTARY ET AL 1999 – 2012






TSS

0 Comments:

Post a Comment

Subscribe to Post Comments [Atom]

<< Home